Visfatin is related to lipid dysregulation, endothelial dysfunction and atherosclerosis in patients with chronic kidney disease

Journal of Nephrology

Volumn 24, Issue 2, 2011, Pages 177-184

  Mu, Jiao ^a   Feng, Bing ^a   Ye, Zilin ^a   Yuan, Fahuan ^a   Zeng, Wei ^a   Luo, Zhifeng ^a   Qi, Wei ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Atherosclerosis; Chronic kidney disease; Endothelial dysfunction; Visfatin

Indexed keywords

C REACTIVE PROTEIN; ENDOTHELIN 1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; NITRIC OXIDE; THROMBOMODULIN; TRIACYLGLYCEROL;

ADULT; ARTERIAL WALL THICKNESS; ARTERY BLOOD FLOW; ARTICLE; ATHEROSCLEROSIS; CAROTID ARTERY; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DISEASE SEVERITY; DISORDERS OF LIPID AND LIPOPROTEIN METABOLISM; ENDOTHELIAL DYSFUNCTION; ENZYME BLOOD LEVEL; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; VASCULAR ENDOTHELIUM; VASODILATATION;

ADULT; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CHRONIC DISEASE; ENDOTHELIN-1; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYPERLIPIDEMIAS; KIDNEY DISEASES; MALE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; NITRIC OXIDE; TRIGLYCERIDES;

EID: 79953693871     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.5301/JN.2010.3488     Document Type: Article

References (31)

1. De Mutsert R, Grootendorst DC, Axelsson J; NECOSAD Study Group. Excess mortality due to interaction between protein energy wasting, inflammation and cardiovascular disease in chronic dialysis patients. Nephrol Dial Transplant. 2008;23:2957-2964.
2. Pecoits-Filho R, Heimbürger O, Bárány P, et al. Associations between circulating inflammatory markers and residual renal function in CRF patients. Am J Kidney Dis. 2003;41:1212-1218.
3. Heimburger O, Stenvinkel P. Adipokines in chronic kidney disease: fat tissue gives nephrologists a message. Perit Dial Int. 2005;25:340-342.
4. Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev. 2006;86:515-581.
5. Axelsson J, Bergsten A, Qureshi AR, Heimbürger O, Barany P, Lönnqvist F. Elevated resistin levels in chronic kidney disease are associated with decreased glomerular filtration rate and inflammation, but not with insulin resistance. Kidney Int. 2006;69:596-604.
6. Chitalia N, Raja RB, Bhandara T, et al. Serum adiponectin and cardiovascular risk in chronic kidney disease and kidney transplantation. J Nephrol. 2010;23:77-84.
7. Malyszko J, Malyszko JS, Kozminski P, Pawlak K, Mysliwiec M. Elevated resistin is related to inflammation and residual renal function in haemodialysed patients. Nephrology. 2007;12:246-253.
8. Samal B, Sun Y, Stearns G. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol. 1994;14:1431-1437.
9. Fukuhara A, Matsuda M, Nishizawa M. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science. 2005;307:426-430.
10. Kaser A, Ludwiczek O, Holzmann S, et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol. 2007;178:1748-1758.
11. Nowell MA, Richards PJ, Fielding CA, et al. Regulation of pre-B cell colony-enhancing factor 17 by e STAT-3-dependent interleukin-6 trans-signaling: implications in the pathogenesis of rheumatoid arthritis. Arthritis Rheum. 2006;54:2084-2095.
12. Ye SQ, Zhang LQ, Adyshev D, et al. Pre-B-cell-colony-enhancing factor is critically involved in thrombin-induced lung endothelial cell barrier dysregulation. Microvasc Res. 2005;70:142-151.
13. Kim SR, Bae YH, Bae SK. Visfatin enhances ICAM-1 and VCAM-1 expression through ROS-dependent NF-kappaB activation in endothelial cells. Biochim Biophys Acta. 2008;1783:886-895.
14. Zhong M, Tan HW. Gong HP. Increased serum visfatin in patients with metabolic syndrome and carotid atherosclerosis. Clin Endocrinol (Oxf). 2008;69:878-884.
15. Dahl TB, Yndestad A, Skjelland M, et al. Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization. Circulation. 2007;115:972-980.**
16. Axelsson J, Witasp A, Carrero JJ. Circulating levels of visfatin/ pre-B-cell colony-enhancing factor 1 in relation to genotype, GFR, body composition, and survival in patients with CKD. Am J Kidney Dis. 2007;49:237-244.
17. Yilmaz MI, Saglam M, Carrero JJ. Serum visfatin concentration and endothelial dysfunction on chronic kidney disease. Nephrol Dial Transplant. 2008;23:959-965.
18. Kato A, Odamaki M, Ishida J, Hishida A. Relationship between serum pre-B cell colony enhancing factor/visfatin and atherosclerotic parameters in chronic hemodialysis patients. Am J Nephrol. 2009;29:31-35.
19. Yilmaz MI, Saqlam M, Carrero JJ. Normalization of endothelial dysfunction following renal transplantation is accompanied by a reduction of circulating visfatin/NAMPT: a novel marker of endothelial damage? Clin Transplant. 2009;23:241-248.
20. O'Keefe JH, Bell DS. Postprandial hyperglycemia/hyperlipidemia (postprandial dysmetabolism) is a cardiovascular risk factor. Am J Cardiol. 2007;100:899-904.
21. Nüsken KD, Petrasch M, Rauh M, et al. Active visfatin is elevated in serum of maintenance haemodialysis patients and correlates inversely with circulating HDL cholesterol. Nephrol Dial Transplant. 2009;24:2832-2838.
22. Liu SW, Qiao SB, Yuan JS, Liu DQ. Association of plasma visfatin levels with inflammation, atherosclerosis, and acute coronary syndromes in humans. Clin Endocrinol (Oxf). 2009;71:202-207.
23. Takebayashi K, Suetsugu M, Wakabayashi S, Aso Y, Inukai T, Association between plasma visfatin and vascular endothelial function in patients with type 2 diabetes mellitus. Metabolism. 2007;56:451-458.
24. Takebayashi K, Suetsugu M, Wakabayashi S. Association beween plasma visfatin and vascular endothelial function in patients with type 2 diabetes mellitus. Metabolism. 2007;56:451-458.
25. Teoh H, Lovren F, Verma S, Vascular dysfunction: a Janus face of visfatin in diabetes? Metabolism. 2007;56:459-61.
26. Zhang T, Berrocal JG, Frizzell KM. Enzymes in the NAD+ salvage pathway regulate SIRT1 activity at target gene promoters. J Biol Chem. 2009;284:20408-20417.
27. Van der Veer E, Nong Z, O'Neil C, Urquhart B, Freeman D, Pickering JG. Pre-B-cell colony-enhancing factor regulates NAD+-dependent protein deacetylase activity and promotes vascular smooth muscle cell maturation. Circ Res. 2005;97:25-34.
28. Adya R, Tan BK, Punn A, Chen J, Randeva HS. Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: novel insights into visfatininduced angiogenesis. Cardiovasc Res. 2008;78:356-365.
29. Paquot N, Tappy L. Adipocytokines: link between obesity, type 2 diabetes and atherosclerosis. Rev Med Liege. 2005;60:369-373.
30. Oki K, Yamane K, Kamei N, Nojima H, Kohno N. Circulating visfatin level is correlated with inflammation, but not with insulin resistance. Clin Endocrinol (Oxf). 2007;67:796-800.
31. Moschen AR, Kaser A, Enrich B, et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol. 2007;178:1748-1758.